SG11202003687RA - Methods of using and compositions containing dulaglutide - Google Patents
Methods of using and compositions containing dulaglutideInfo
- Publication number
- SG11202003687RA SG11202003687RA SG11202003687RA SG11202003687RA SG11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- compositions containing
- dulaglutide
- containing dulaglutide
- compositions
- Prior art date
Links
- 229960005175 dulaglutide Drugs 0.000 title 1
- 108010005794 dulaglutide Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003687RA true SG11202003687RA (en) | 2020-06-29 |
Family
ID=64572530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003687RA SG11202003687RA (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Country Status (22)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3937904A1 (en) * | 2019-03-15 | 2022-01-19 | Eli Lilly and Company | Preserved formulations |
| JP2023513054A (ja) * | 2020-01-30 | 2023-03-30 | イーライ リリー アンド カンパニー | デュラグルチドの治療的使用 |
| JP2023525898A (ja) * | 2020-05-19 | 2023-06-19 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE437891T1 (de) | 2000-12-07 | 2009-08-15 | Lilly Co Eli | Glp-1 fusionsproteine |
| US7452966B2 (en) | 2003-06-12 | 2008-11-18 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| CA2589647A1 (en) | 2004-12-22 | 2006-06-29 | Eli Lilly And Company | Glp-1 analog fusion protein formulations |
| HRP20110242T1 (hr) | 2007-07-10 | 2011-05-31 | Eli Lilly And Company | Formulacija s fuzijskim proteinom glp-1-fc |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| PL3630164T3 (pl) | 2017-06-01 | 2024-01-29 | Eli Lilly And Company | Dulaglutyd do leczenia przewlekłej choroby nerek |
-
2018
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 CA CA3082625A patent/CA3082625A1/en active Pending
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt unknown
- 2018-11-13 JO JOP/2020/0126A patent/JOP20200126A1/ar unknown
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en active IP Right Grant
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP2022062153A/ja active Pending
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274276A (en) | CASZ preparations and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| IL257307B (en) | Transgenic crispr–cas9 preparations and methods of use | |
| IL256621A (en) | Carrier-binder preparations and methods for their preparation and use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| IL276135A (en) | Preparations and methods of use | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| ZA202004531B (en) | Compositions containing thymohydroquinone and their method of preparation | |
| SMT202200069T1 (it) | Composizioni peptidiche e metodi di utilizzo | |
| ZA202000502B (en) | Cosmetic compositions and methods of use | |
| IL282533A (en) | Oligosaccharide preparations and methods of using them | |
| IL275739A (en) | Preparations for cryopreservation and methods of their use | |
| IL274563A (en) | Methods of use and preparations containing dolaglutide | |
| SG11201803284YA (en) | Novel method of use and compositions | |
| EP3253396A4 (en) | Probiotic compositions and methods of use | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| EP3256094A4 (en) | Dental compositions and methods of use | |
| EP3504267C0 (en) | OLIGOESTER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | |
| IL261794A (en) | Preparations and methods for using them | |
| SG11202002351SA (en) | Poloxamer compositions and methods of making and using same | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| HK40027593A (en) | Methods of using and compositions containing dulaglutide | |
| HK40036149A (en) | Cas12c compositions and methods of use | |
| HK40036150A (en) | Casz compositions and methods of use |